

Atty. Dkt. No. 030307-0250



## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:

Allan Otto Fog LIHME et al.

Title:

AN EXTRACORPOREAL STABILISED EXPANDED BED

ADSORPTION METHOD FOR THE TREATMENT OF SEPSIS

Appl. No.:

10/520,685

Filing Date:

05/27/2005

Examiner:

Unassigned

Art Unit:

1614

## SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT UNDER 37 CFR §1.56

Mail Stop Amendment Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

Submitted herewith on Form PTO/SB/08 is a listing of documents known to Applicants in order to comply with Applicants' duty of disclosure pursuant to 37 CFR §1.56.

A copy of each non-U.S. patent document and each non-patent document is being submitted to comply with the provisions of 37 CFR §1.97 and §1.98.

The submission of any document herewith, which is not a statutory bar, is not intended as an admission that such document constitutes prior art against the claims of the present application or that such document is considered material to patentability as defined in 37 CFR §1.56(b). Applicants do not waive any rights to take any action which would be appropriate to antedate or otherwise remove as a competent reference any document which is determined to be a *prima facie* art reference against the claims of the present application.

## TIMING OF THE DISCLOSURE

The listed documents are being submitted in compliance with 37 CFR §1.97(b), before the mailing date of the first Office Action on the merits.

## RELEVANCE OF EACH DOCUMENT

All of the documents are in English.

Applicants respectfully request that each listed document be considered by the Examiner and be made of record in the present application and that an initialed copy of Form PTO/SB/08 be returned in accordance with MPEP §609.

The Commissioner is hereby authorized to charge any additional fees which may be required regarding this application under 37 CFR §§ 1.16-1.17, or credit any overpayment, to Deposit Account No. 19-0741. Should no proper payment be enclosed herewith, as by a check being in the wrong amount, unsigned, post-dated, otherwise improper or informal or even entirely missing, the Commissioner is authorized to charge the unpaid amount to Deposit Account No. 19-0741.

conser 2005 By

Respectfully submitted,

FOLEY & LARDNER LLP Customer Number: 22428

Telephone:

(202) 672-5404

Facsimile:

(202) 672-5399

Stephen A. Bent Attorney for Applicant Registration No. 29,768

MODIFIED PTO/SB/08 (08-00)

Approved for use through 10/31/2002. OMB 0651-0031 U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number Substitute for form 1449B/PTO Complete if Known Application Number 10/520,685 INFORMATION DISCLOSURE STATEMENT BY APPLICANT Filing Date 05/27/2005 Allan Otto Fog LIHME First Named Inventor Date Submitted: September 20, 2005 Group Art Unit 1614 (use as many sheets as necessary) **Examiner Name** Unassigned Sheet 1 1 Attorney Docket Number 030307-0250

U.S. PATENT DOCUMENTS							
Examiner Initials*	Cite No.¹	U.S. Patent Document		Name of Patentee or Applicant of Cited	Date of Publication of	Pages, Columns, Lines, Where Relevant Passages or Relevant	
		Number	Kind Code <sup>2</sup> ( <i>if</i> known)	- Document	Cited Document MM-DD-YYYY	Figures Appear	

Examiner Initials*	Cite No.1	Foreign Patent Document			Name of Patentee or	Date of Publication of Cited Document	Pages, Columns, Lines, Where Relevant	7
		Office <sup>3</sup>	Number <sup>4</sup>	Kind Code <sup>5</sup> ( <i>if known</i> )	Applicant of Cited Documents	MM-DD-YYYY	Passages or Relevant Figures Appear	Te

		NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No.1	item (book magazine journal certal cympocium catalog etc.) date page(c) volume-icque number(c) publicher city and/or country where				
	B1	Greg S. MARTIN M.D., "The Epidemiology of Sepsis in the United States from 1979 through 2000", The New England Journal of Medicine, 348:16, April 2003, pp. 1546-1554.				
	B2	Jose Carlos GUTIERREZ-RAMOS et al., "Molecules and Mechanisms Operating in Septic Shock; Lessons from Knockout Mice", Immunology Today, 18. July 1997, pp. 329-334.				
	B3	Bertrand L. JABER MD et al., "Extracorporeal Absorbent-Based Strategies in Sepsis", American Journal of Kidney Diseases, Vol. 30, No. 5, Suppl. 4, (November 1997) pp. S44-S56.				
	B4	Rinaldo BELLOMO et al., "Extracorporeal Blood Purification Therapy for Sepsis and Systemic Inflammation: Its Biological Rationale", Blood Purification in Intensive Care, Contrib. Nephrol. Basel. Karger. 2001, vol. 132, pp. 367-374.				
	B5	F. STRUTZ et al., "Relationship of antibodies to endotoxin core to mortality in medical patients with sepsis syndrome", Intensive Care Med (1999) 25: 435-444.				
	B6	Robert E W HANCOCK, Cationic peptides: effectors in innate immunity and novel antimicrobials", THE LANCET Infectious Diseases Vol. 1, October 2001, 156-164.				
	B7	Hisataka SHOJI et al., "Extracorporeal Endotoxin Removal by Polymyxin B Immobilized Fiber Cartridge: Designed and Antiendotoxin Efficacy in the Clinical Application", Therapeutic Apheresis, 2(1), 1998, pp. 3-12.				
	88	Hironori NEMOTO et al., "Newly Developed Immobilized Polymyxin B Fibers Improve the Survival of Patients with Sepsis", Blood Purification, 2001; 19:361-369.				

	4 15 14 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1		
Examiner Signature		Date Considered	

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>&</sup>lt;sup>1</sup> Unique citation designation number. <sup>2</sup>See attached Kinds of U.S. Patent Documents. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.